SEC Tracker
Get the app

Pulmatrix PULM

Pulmatrix FY 2023: revenue $7.3M, up 20%; diluted EPS −$3.87

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Pulmatrix reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$7.3M+20% from $6.1M in FY 202210-K income statement, on EDGAR
  2. Net income−$14.1MAgainst −$18.8M in FY 202210-K income statement, on EDGAR
  3. Diluted EPS−$3.87Against −$5.46 in FY 202210-K income statement, on EDGAR
  4. Cash and cash equivalents$19.2M−46% from $35.6M in FY 202210-K balance sheet, on EDGAR
  5. Cash from operations−$16.0MAgainst −$19.4M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Pulmatrix files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Curis CRIS public float $25M, Jun 30, 2025
  2. Scynexis SCYX public float $26M, Jun 30, 2025
  3. Palatin Technologies PTN public float $26M, Dec 31, 2025
  4. Kala Bio KALA public float $25M, Jun 30, 2025
  5. Lexaria Bioscience LEXX public float $25M, Feb 28, 2025, over 18 months old